Affordable Access

deepdyve-link
Publisher Website

Pharmacotherapy of heparin-induced thrombocytopenia: therapeutic options and challenges in the clinical practices.

Authors
  • Al-Eidan, Fahad A S1
  • 1 College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. Electronic address: [email protected] , (Saudi Arabia)
Type
Published Article
Journal
Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing
Publication Date
March 2015
Volume
33
Issue
1
Pages
10–20
Identifiers
DOI: 10.1016/j.jvn.2014.07.001
PMID: 25700733
Source
Medline
License
Unknown

Abstract

Heparin-induced thrombocytopenia (HIT) is an immune response to heparin associated with significant morbidity and mortality in hospitalized patients if unidentified as soon as possible, owing to thromboembolic complications involving both arterial and venous systems. Early diagnoses based on a comprehensive interpretation of clinical and laboratory information improves clinical outcomes. Management principles of strongly suspected HIT should not be delayed for laboratory result confirmation. Treatment strategies have been introduced including new, safe, and effective agents. This review summarizes the clinical therapeutic options for HIT addressing the use of parenteral direct thrombin inhibitors and indirect factor Xa inhibitors as well as the potential non-vitamin K antagonist oral anticoagulants.

Report this publication

Statistics

Seen <100 times